All Stories

  1. Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer

    Article • American Journal of Clinical Oncology, December 2014, Wolters Kluwer Health

    Dr Pamela Biondani

  2. Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study

    Article • Cancer, April 2014, Wiley

    Dr Pamela Biondani

  3. Targeted treatments in advanced renal cell carcinoma: focus on axitinib

    Article • Pharmacogenomics and Personalized Medicine, March 2014, Taylor & Francis

    Dr Pamela Biondani

  4. <b><i>TP53</i></b> Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon

    Article • Oncology, January 2014, Karger Publishers

    Dr Pamela Biondani

  5. Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation

    Article • Annals of Oncology, December 2013, Oxford University Press (OUP)

    Dr Pamela Biondani

  6. Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens

    Article • Cancer Biology & Therapy, December 2013, Taylor & Francis

    Dr Pamela Biondani

  7. P035 Sequential targeted therapy with sunitinib-sorafenib (SU-SO) versus sorafenib-sunitinib (SO-SU) in metastatic renal cell carcinoma: Results from a large cohort of patients

    Article • European Urology Supplements, November 2013, Elsevier

    Dr Pamela Biondani

  8. Role of cMET in the Development and Progression of Colorectal Cancer

    Article • International Journal of Molecular Sciences, September 2013, MDPI AG

    Dr Pamela Biondani

  9. Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT

    Article • Targeted Oncology, July 2013, Springer Science + Business Media

    Dr Pamela Biondani

  10. Role of BAX for outcome prediction in gastrointestinal malignancies

    Article • Medical Oncology, May 2013, Springer Science + Business Media

    Dr Pamela Biondani

  11. Future Directions in Metastatic Castration Resistant Prostate Cancer (mCRPC): Clinical Rationale and Use of New-Generation Hormonal Therapies

    Article • Journal of Cancer Therapy, January 2013, Scientific Research Publishing, Inc,

    Dr Pamela Biondani

  12. Is the Standardized Uptake Value of FDG-PET/CT Predictive of Pathological Complete Response in Locally Advanced Rectal Cancer Treated with Capecitabine-Based Neoadjuvant Chemoradiation?

    Article • Oncology, January 2013, Karger Publishers

    Dr Pamela Biondani

  13. Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients

    Article • Clinical & Translational Oncology, November 2012, Springer Science + Business Media

    Dr Pamela Biondani

  14. Adjuvant treatment of colorectal cancer in the elderly: Where do we come from and where are we going?

    Article • Journal of Solid Tumors, June 2012, Sciedu Press

    Dr Pamela Biondani

  15. Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab

    Article • Medical Oncology, January 2012, Springer Science + Business Media

    Dr Pamela Biondani

  16. 7149 POSTER Sequential Use of Targeted Therapies (TT) in Metastatic Renal Cell Cancer (mRCC): Overall Results of a Large Experience

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Pamela Biondani

  17. 6628 POSTER A Combination of RAD001 and Octreotide LAR as First-line Treatment of Well Differentiated Neuroendocrine Tumours – an I.T.M.O. (Italian Trials in Medical Oncology) Group Study

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Pamela Biondani

  18. 6626 POSTER Efficacy and Safety of RAD001 as Second Line Therapy in Biliary Tract Cancer (BTC) Patients (pts) – a Phase II I.T.M.O. (Italian Trials in Medical Oncology) Group Study

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Pamela Biondani

  19. 6608 POSTER Bax and p53 as Outcome Predictive in Metastatic Gastric Cancer (MGC) Patients Treated With First-Line COI (Capecitabine, Oxaliplatin, and Irinotecan) Regimen

    Article • European Journal of Cancer, September 2011, Elsevier

    Dr Pamela Biondani